ProQuest Investments

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

Telormedix is a biopharmaceutical company dedicated to developing targeted therapies that harness the innate immune system for the treatment of cancer and autoimmune diseases. The company focuses on creating innovative biopharmaceutical drugs that utilize a clinically active small molecule compound known for its favorable safety profile. By targeting specific immunotherapeutic pathways, Telormedix aims to enhance treatment options for patients suffering from cancer and infectious diseases, ultimately striving for improved medical outcomes.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.

Telormedix is a biopharmaceutical company dedicated to developing targeted therapies that harness the innate immune system for the treatment of cancer and autoimmune diseases. The company focuses on creating innovative biopharmaceutical drugs that utilize a clinically active small molecule compound known for its favorable safety profile. By targeting specific immunotherapeutic pathways, Telormedix aims to enhance treatment options for patients suffering from cancer and infectious diseases, ultimately striving for improved medical outcomes.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

Aires Pharmaceuticals, Inc., a clinical stage pharmaceutical company, develops therapies to treat pulmonary disorders. The company offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia, and other respiratory infections. It also develops products for the treatment of bacterial pulmonary infections. Aires Pharmaceuticals was founded in 2006 and is based in San Diego, California.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Predictive Biosciences, Inc. is a molecular diagnostics company focused on developing diagnostic products aimed at enhancing cancer management. Founded in 2006 and headquartered in Lexington, Massachusetts, the company specializes in proteomics and oncology, particularly in the area of tumor biomarkers. Predictive Biosciences offers a range of assays that detect urinary biomarkers, which are indicative of the physiological changes associated with cancer development and progression. Among its key products are the Triage Monitoring Assay, which enables physicians to postpone invasive diagnostic procedures, the Interval Monitoring Assay for cancer surveillance between follow-up appointments, and the Stratification Assay to assist physicians in managing patient care decisions.

Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.

Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

ORTHOCON is a medical therapeutics company developing innovative absorbable products for orthopaedic and spine surgeries.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.

Biosyntech Inc. is a Canadian company focused on developing biotherapeutic thermogels for tissue repair and the delivery of therapeutic agents. Its technology platform, known as BST-Gel, utilizes hydrogels made from chitosan, a natural biopolymer sourced from crustacean shells. The company's leading products currently in clinical trials include BST-CarGel for cartilage repair, BST-DermOn for wound healing, and BST-InPod, which aims to treat chronic pain associated with plantar fat pad atrophy in the heel and forefoot. Additionally, Biosyntech is involved in clinical studies for BST-InPod in collaboration with Nicholas Piramal India, Ltd. The company, incorporated in 1994, is headquartered in Laval, Canada.

Zosano Pharma Corporation is a clinical stage biopharmaceutical company based in Fremont, California, established in 2006. The company specializes in developing therapeutics for migraine sufferers through its innovative intracutaneous microneedle delivery system. Its primary product candidate, Qtrypta (M207), is a proprietary formulation of zolmitriptan aimed at treating migraines. Zosano Pharma is committed to discovering and developing drug candidates that meet significant unmet medical needs and have strong commercialization potential.

Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.

ORTHOCON is a medical therapeutics company developing innovative absorbable products for orthopaedic and spine surgeries.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Telormedix is a biopharmaceutical company dedicated to developing targeted therapies that harness the innate immune system for the treatment of cancer and autoimmune diseases. The company focuses on creating innovative biopharmaceutical drugs that utilize a clinically active small molecule compound known for its favorable safety profile. By targeting specific immunotherapeutic pathways, Telormedix aims to enhance treatment options for patients suffering from cancer and infectious diseases, ultimately striving for improved medical outcomes.

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Excaliard is a newly formed, venture capital-funded biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases.

Zosano Pharma Corporation is a clinical stage biopharmaceutical company based in Fremont, California, established in 2006. The company specializes in developing therapeutics for migraine sufferers through its innovative intracutaneous microneedle delivery system. Its primary product candidate, Qtrypta (M207), is a proprietary formulation of zolmitriptan aimed at treating migraines. Zosano Pharma is committed to discovering and developing drug candidates that meet significant unmet medical needs and have strong commercialization potential.

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule IND candidates against clinically validated therapeutic targets, focused primarily on the treatment of Cancer and infectious diseases.

5asec is a textile care brand that provides its customers with dry cleaning and laundry services. 5asec provides its services in 3 segments, including basic services: dry cleaning, professional washing and steam ironing, and stain cleaning; professional services: duvet and home linen treatment, alterations services; and carpets, furniture, and leather cleaning; and textile care solutions: maxima treatment, appret finish, anti-moth and dust mites’ repellent solutions, and water repellent treatments. 5asec is headquartered in Geneva, Switzerland.

Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies aimed at treating heterogeneous solid tumors. The company utilizes innovative platform technologies, including the Sleeping Beauty system, which enables the genetic engineering of immune cells to enhance T-cell functionality for cancer treatment. Alaunos is advancing several therapies, notably Ad-RTS-hIL-12 combined with veledimex, which is currently in Phase 2 trials for recurrent glioblastoma multiforme. Additionally, the company is exploring chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies, leveraging collaborations with renowned institutions such as MD Anderson Cancer Center. The RheoSwitch Therapeutic System is another key technology employed by Alaunos, allowing for precise modulation of gene expression to improve cancer treatment outcomes. Founded in 1998 and based in Boston, Massachusetts, Alaunos is committed to advancing its portfolio of immuno-oncology solutions to address unmet medical needs in cancer care.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies aimed at treating heterogeneous solid tumors. The company utilizes innovative platform technologies, including the Sleeping Beauty system, which enables the genetic engineering of immune cells to enhance T-cell functionality for cancer treatment. Alaunos is advancing several therapies, notably Ad-RTS-hIL-12 combined with veledimex, which is currently in Phase 2 trials for recurrent glioblastoma multiforme. Additionally, the company is exploring chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies, leveraging collaborations with renowned institutions such as MD Anderson Cancer Center. The RheoSwitch Therapeutic System is another key technology employed by Alaunos, allowing for precise modulation of gene expression to improve cancer treatment outcomes. Founded in 1998 and based in Boston, Massachusetts, Alaunos is committed to advancing its portfolio of immuno-oncology solutions to address unmet medical needs in cancer care.

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Guava Technologies, Inc. is a biotechnology and medical device company specializing in the development and manufacturing of flow cytometry systems. Founded in 1998 and headquartered in Hayward, California, the company provides a range of products designed for applications in cell biology research, drug discovery, and clinical diagnostics, with a specific focus on HIV/AIDS monitoring. Its offerings include assays for cell counting and viability, antibody quantification, apoptosis, cell cycle, cytotoxicity, and cell proliferation. Guava Technologies serves various markets, including life science research and core flow cytometry, contributing to advancements in cellular analysis. The company operates as a subsidiary of Millipore Corp.

EUSA Pharma, established in March 2015 and headquartered in the UK, is a specialty pharmaceutical company with a global presence, particularly in Europe and the USA. The company specializes in oncology and critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. EUSA Pharma focuses on addressing rare diseases and conditions like oral mucositis, a debilitating side effect of cancer treatments, with effective biopharmaceutical solutions. The firm submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. EUSA Pharma aims to expand its product offerings through acquisitions and in-licensing, supported by significant funding from prominent life science investors. With direct commercial operations and a distribution network that spans approximately 40 countries, EUSA Pharma is well-positioned to meet the needs of patients worldwide.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.

Guava Technologies, Inc. is a biotechnology and medical device company specializing in the development and manufacturing of flow cytometry systems. Founded in 1998 and headquartered in Hayward, California, the company provides a range of products designed for applications in cell biology research, drug discovery, and clinical diagnostics, with a specific focus on HIV/AIDS monitoring. Its offerings include assays for cell counting and viability, antibody quantification, apoptosis, cell cycle, cytotoxicity, and cell proliferation. Guava Technologies serves various markets, including life science research and core flow cytometry, contributing to advancements in cellular analysis. The company operates as a subsidiary of Millipore Corp.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.